Pfizer Inc. (NYSE:PFE) Shares Sold by Hudson Valley Investment Advisors Inc. ADV

Hudson Valley Investment Advisors Inc. ADV decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 156,097 shares of the biopharmaceutical company’s stock after selling 21,117 shares during the period. Hudson Valley Investment Advisors Inc. ADV’s holdings in Pfizer were worth $4,141,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of PFE. Strategic Financial Concepts LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at about $38,000. Quest Partners LLC acquired a new stake in shares of Pfizer during the 2nd quarter valued at approximately $570,000. Angeles Wealth Management LLC lifted its position in shares of Pfizer by 24.0% during the 2nd quarter. Angeles Wealth Management LLC now owns 11,580 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 2,239 shares during the period. AGF Management Ltd. grew its holdings in shares of Pfizer by 6.7% in the 2nd quarter. AGF Management Ltd. now owns 1,223,841 shares of the biopharmaceutical company’s stock worth $34,243,000 after acquiring an additional 76,464 shares during the period. Finally, HHM Wealth Advisors LLC increased its stake in Pfizer by 9.3% in the 2nd quarter. HHM Wealth Advisors LLC now owns 6,311 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 538 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on PFE shares. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Citigroup began coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Guggenheim dropped their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $26.92 on Friday. The stock has a fifty day moving average price of $26.21 and a 200 day moving average price of $28.05. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm has a market capitalization of $152.56 billion, a P/E ratio of 36.38, a PEG ratio of 0.63 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the company posted ($0.17) EPS. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.39%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 232.43%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.